Naltrexone Overview, Dosing & Safety | Peptide Database

Naltrexone (LDN)

Opioid Antagonist | Low-Dose Anti-Inflammatory & Immune Modulation

Community Research

Join others researching Naltrexone — share findings, ask questions, and learn from real experiences

Naltrexone is an opioid receptor antagonist originally developed and FDA-approved at full dose (50 mg) for the treatment of opioid and alcohol use disorders. At this dose, it competitively blocks mu-opioid receptors, preventing the euphoric and reinforcing effects of opioids and reducing alcohol cravings. However, naltrexone has gained enormous popularity in the biohacking and functional medicine communities at dramatically lower doses (1-4.5 mg), commonly referred to as Low-Dose Naltrexone (LDN). At these sub-therapeutic doses, naltrexone produces a brief, transient blockade of opioid receptors lasting only a few hours, which triggers a compensatory upregulation of endogenous endorphins and enkephalins. This rebound effect, combined with direct modulation of the Opioid Growth Factor (OGF) - OGF receptor axis, produces broad anti-inflammatory and immunomodulatory effects that have shown promise across a wide range of autoimmune, inflammatory, and chronic pain conditions.

At low doses (1-4.5 mg), naltrexone produces a brief nocturnal blockade of opioid receptors that lasts approximately 4-6 hours. This transient blockade triggers a compensatory upregulation of endogenous opioid production, including beta-endorphin and met-enkephalin (also known as Opioid Growth Factor, OGF). Elevated OGF interacts with the OGF receptor (OGFr) to modulate cell proliferation and immune function. LDN also directly antagonizes Toll-like receptor 4 (TLR4) on microglia and macrophages, reducing neuroinflammation and systemic inflammatory cytokine production including TNF-alpha, IL-6, and IL-12. The net effect is a shift from a pro-inflammatory Th1/Th17-dominant immune profile toward a more balanced regulatory state. Additionally, LDN has been shown to increase circulating endorphin levels by 200-300%, which contributes to improved mood, reduced pain perception, and enhanced immune surveillance. The bedtime dosing strategy is deliberate: the brief receptor blockade occurs during the natural nocturnal endorphin surge, maximizing the compensatory rebound effect.

Molecular Data

Research Indications

LDN has shown benefit across a broad spectrum of autoimmune diseases including Hashimoto's thyroiditis, rheumatoid arthritis, lupus, and multiple sclerosis. The immune-modulating effects via TLR4 antagonism and OGF upregulation help rebalance dysregulated immune responses. Multiple case series and small trials report symptom improvement and reduced inflammatory markers.

Several clinical trials have demonstrated benefit in Crohn's disease, with one RCT showing a 67% response rate and 33% remission rate with LDN 4.5 mg versus placebo. Improvements in mucosal healing and quality of life scores have been reported. Preliminary data in ulcerative colitis are also encouraging.

Observational studies and small trials suggest LDN may improve quality of life, reduce fatigue, and modestly decrease relapse rates in MS patients. A pilot trial showed improvements in mental health quality of life scores. LDN is often used as adjunctive therapy alongside disease-modifying treatments.

Two randomized controlled trials have demonstrated that LDN (4.5 mg) significantly reduces pain severity (approximately 30% reduction from baseline), improves overall satisfaction with life, and enhances mood in fibromyalgia patients. Responders showed greater reductions in inflammatory markers including ESR.

Anecdotal reports and small observational studies suggest LDN may reduce fatigue severity and improve functional capacity in ME/CFS patients. The anti-neuroinflammatory mechanism via TLR4 antagonism on microglia is a plausible pathway. Larger controlled trials are needed.

Case reports and small case series document meaningful pain reduction and functional improvement with LDN in CRPS patients. The combination of anti-neuroinflammatory and endorphin-enhancing effects makes LDN a plausible adjunctive therapy for this difficult-to-treat condition.

By upregulating endogenous endorphins and modulating the opioid reward system, LDN may address anhedonia (inability to feel pleasure) - a symptom poorly addressed by conventional antidepressants. Preliminary studies and clinical experience suggest benefits for mood and motivation, particularly in patients with inflammation-driven depression.

Dosing Protocols

Naltrexone is administered orally. Full-dose naltrexone (50 mg) is available as a standard pharmaceutical tablet (ReVia). Low-Dose Naltrexone (1-4.5 mg) is typically obtained as a compounded capsule or liquid from a compounding pharmacy, as commercial formulations at these low doses are not widely manufactured. Some practitioners prescribe commercially available 50 mg tablets to be dissolved in measured volumes of water or other vehicle for precise low-dose self-preparation, though compounded capsules are preferred for dosing accuracy.

Low-Dose Naltrexone (LDN) - Standard Protocol

1.5 mg, titrate to 4.5 mg

Once daily at bedtime

Oral

LDN - Ultra-Low Starting Dose (Sensitive Patients)

0.5-1.0 mg, titrate slowly to 4.5 mg

Full-Dose - Opioid Dependence (FDA-Approved)

50 mg/day

Once daily

Full-Dose - Alcohol Dependence (FDA-Approved)

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Vivid dreams or unusually intense dreaming - the most frequently reported side effect, typically diminishes over 1-2 weeks

Initial sleep disruption or insomnia during the first week of treatment

Mild nausea, particularly during the first few days

Transient headache during dose initiation or titration

Stop Signs - Discontinue if:

Signs of precipitated opioid withdrawal (severe abdominal cramping, vomiting, diarrhea, muscle aches, anxiety) - indicates undisclosed or unrecognized opioid use

Severe or persistent nausea, vomiting, or abdominal pain

Jaundice or signs of hepatic dysfunction (primarily a concern at full 50 mg dosing)

Severe allergic reaction (rash, swelling, difficulty breathing)

Contraindications

Current use of opioid medications or active opioid dependence (must be opioid-free 7-10 days minimum)

Acute hepatitis or severe hepatic impairment (primarily relevant at full dose)

Known hypersensitivity to naltrexone

Anticipated need for opioid pain medication (e.g., upcoming surgery - discontinue LDN 3-7 days prior)

Quality Checklist

Good Signs

Compounded by a licensed, reputable compounding pharmacy (PCAB-accredited preferred)

Capsules contain only naltrexone with inert filler (microcrystalline cellulose or similar)

Proper labeling with dose, lot number, and beyond-use date

Prescribed by licensed physician or practitioner familiar with LDN protocols

Consistent dosing with verified potency testing

Warning Signs

Compounded formulations with unnecessary additives, fillers, or slow-release agents that may alter absorption

Self-preparation from crushed full-dose tablets without proper volumetric measurement

Sourced from overseas pharmacies without verification of compound identity and purity

Bad Signs

No labeling, incorrect dosage, or missing beyond-use date

Capsules with visible inconsistency in size, color, or fill volume

Obtained without any medical consultation or prescription

Sourced from unregulated suppliers with no quality assurance

Frequently Asked Questions

Can I take LDN if I use opioid pain medication?

Absolutely not -- naltrexone at any dose will block opioid effects and precipitate acute withdrawal. You must be opioid-free for 7-10 days before starting LDN, and discontinue LDN for 3-7 days before surgery or any procedure requiring opioid pain management. Do not combine these under any circumstances.

Why do I have vivid dreams on LDN?

Vivid dreams are the most common early side effect and are actually considered a sign the compound is active. They occur because naltrexone's transient opioid blockade during the nocturnal endorphin surge affects sleep architecture. Vivid dreams typically diminish significantly after 1-2 weeks, though some people continue to experience them mildly. Starting at 0.5-1.5 mg reduces dream intensity.

How long before LDN reduces pain or autoimmune symptoms?

The anti-inflammatory effects are cumulative. Most users see initial improvements in energy and mood within 2-4 weeks. Significant pain reduction in fibromyalgia typically appears by week 6-12, while autoimmune markers may take 3-6 months to show measurable improvement. Don't expect rapid symptomatic relief like you would with NSAIDs or corticosteroids.

Can I cycle LDN on and off?

Unlike some compounds, LDN has no tolerance development and no dependence risk, so indefinite continuous use is generally safe. However, many practitioners do recommend periodic reassessment at 6-12 month intervals to verify continued necessity and optimize dosing. There's no established benefit to cycling it off if it's working well.

References

Comprehensive review of LDN's mechanisms and clinical applications. Identifies TLR4 antagonism and OGF-OGFr upregulation as primary mechanisms of action. Summarizes evidence across fibromyalgia, Crohn's disease, multiple sclerosis, and cancer, noting that LDN is well-tolerated with minimal side effects.

Randomized controlled trial demonstrating that LDN (4.5 mg/day) significantly reduced fibromyalgia pain by approximately 30% compared to placebo, with improvements in general satisfaction with life and mood. Greater pain reduction was associated with lower baseline ESR, suggesting an anti-inflammatory mechanism.

Pilot clinical trial showing that LDN (4.5 mg nightly) produced a 67% response rate and 33% remission rate in patients with active Crohn's disease over 12 weeks. Significant improvements in Crohn's Disease Activity Index scores and quality of life measures were observed with no serious adverse events.

Early mechanistic paper proposing that LDN exerts anti-inflammatory effects primarily through antagonism of TLR4 on microglia and macrophages, reducing central and peripheral neuroinflammation. This mechanism is distinct from opioid receptor effects and explains LDN's efficacy in inflammatory pain conditions.

Detailed review of the OGF-OGFr axis and its role in mediating LDN's therapeutic effects. OGF (met-enkephalin) upregulation following transient opioid receptor blockade modulates immune cell proliferation, T-cell function, and inflammatory responses. Provides the mechanistic foundation for LDN's broad immunomodulatory properties.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.